Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibepolimab plus platinum and pucotenlimab induction followed by concurrent radiotherapy plus vibepolimab for advanced cervical cancer
ChiCTR2600131531Phase 2Not yet recruiting
- Sponsor
- Huizhou Central People's Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vibepolimab and pucotenlimab in Cervical Cancer (CC), sponsored by Huizhou Central People's Hospital. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
vibepolimabpucotenlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600131531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131531.